Canaccord Genuity Maintains a 'Hold' on Medifast (MED); Management Change At The Top, Probably More To Come
Get Alerts MED Hot Sheet
Price: $11.69 +3.54%
Rating Summary:
4 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 13
Rating Summary:
4 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 9 | New: 13
Join SI Premium – FREE
Canaccord Genuity maintains a 'Hold' on Medifast (NYSE: MED) price target of $16.00.
Analyst, Scott Van Winkle, said, "The new CEO (Current Chairman) has ample executive leadership experience and we do not see the change as a negative for MED. However, we expect further management changes could be likely...We maintain our rating and expect Q4 results will again fall short of consensus; we look for a resetting of F2012 forecasts as we do not believe that the consensus estimates respect the high level of investments in the clinic operation slated over the next 12 to 18 months."
For an analyst ratings summary and ratings history on Medifast click here. For more ratings news on Medifast click here.
Shares of Medifast closed at $16.10 yesterday.
Analyst, Scott Van Winkle, said, "The new CEO (Current Chairman) has ample executive leadership experience and we do not see the change as a negative for MED. However, we expect further management changes could be likely...We maintain our rating and expect Q4 results will again fall short of consensus; we look for a resetting of F2012 forecasts as we do not believe that the consensus estimates respect the high level of investments in the clinic operation slated over the next 12 to 18 months."
For an analyst ratings summary and ratings history on Medifast click here. For more ratings news on Medifast click here.
Shares of Medifast closed at $16.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Moderna (MRNA) to Neutral
- Legence Corp (LGN) PT Raised to $130 at Tigress Financial Partners
- Viking Holdings (VIK) PT Raised to $121 at UBS Ahead of Q2 Earnings
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share